印度疫情持續惡化 內地原料藥股聯邦製藥及新華製藥曾漲12%-14% 四環醫藥再探頂
印度昨天新冠確診病例接近35萬人,連續第四天錄得超過30萬人確診,屢創全球單日紀錄高。有分析指,印度疫情持續惡化,當地原料藥廠若因疫情而關閉產能,將有利中國藥廠市佔率提升。內地原料藥股聯邦製藥(03933.HK)今早曾越牛熊線(6.81元),漲近12%高見7.03元,現造6.76元,回升7.3%,成交急增至1,399萬股;新華製藥(00719.HK)三連漲,今早曾急漲14%至5.47元,暫受制今年2月所創高位,現造5.14元,續升7.3%,成交急增至376萬股。
四環醫藥(00460.HK)繼上周五整固後,今早股價再探頂,最高見3.4元,再創近四年高,現報3.34元,回升7.7%,成交已達1.2億股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.